In July, the six viral marker assay conversion at CTS Dallas, Phoenix and Tampa laboratories was achieved with minimal disruption and substantial cost saving to our healthcare partners.
In 2016, CTS tested more source plasma samples (4.9 million) than blood donor samples (4.5 million).
CTS Tampa lab implemented the Ortho Clinical Diagnostics VITROS® testing platform to perform COVID-1...
In August CTS begins source plasma testing as a new line of business to one of the largest plasma fr...
CTS embraces a company-wide operational excellence initiative designed to change the culture to enha...
CTS Tampa lab implements Dengue testing on behalf of a healthcare partner in an endemic area.
CTS Research Consortium was established to further CTS’s leadership in infectious disease research....